A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
NCT07566052
This study is recruiting at 7 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. The first treatment is usually chemotherapy, given with another treatment that targets specific proteins on cancer cells. If the cancer gets worse, the next main treatment is usually a medicine called docetaxel. This treatment doesn't stop most people's cancer from getting worse for very long. Other treatments are needed to improve outcomes in people with NSCLC. Genes give your body instructions on how to make proteins. Proteins are needed to keep the body working properly.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Non-small Cell Lung Cancer (NSCLC)
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Astellas Pharma Global Development, Inc.
- Last updated on ClinicalTrials.gov
- October 8, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 3
- Oncura Health d.b.a.Los Angeles Cancer Network · Glendale, CA
- UCLA Health - Santa Monica Cancer Care · Los Angeles, CA
- UCSF Health - UCSF Helen Diller Family Comprehensive Cancer Center · San Francisco, CA
New Jersey · 2
- Astera Cancer Care · Edison, NJ
- Rutgers Cancer Institute of New Jersey · New Brunswick, NJ
Texas · 1
- Texas Oncology-Longview Cancer Center · Longview, TX
Virginia · 1
- Virginia Cancer Specialists · Arlington, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.